Celgene, following BMS buyout, forms two immuno-oncology partnerships
The company said Friday morning that it would partner with two companies, Kyn Therapeutics and Obsidian Therapeutics.
The company said Friday morning that it would partner with two companies, Kyn Therapeutics and Obsidian Therapeutics.